Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor withdrawal

Conditions

Locally Advanced Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Unresectable Pancreatic Adenocarcinoma

Interventions

DRUG: Onvansertib
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
PROCEDURE: Electrocardiography
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
PROCEDURE: Biospecimen Collection
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]